{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:57:22Z","timestamp":1793055442039,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"AstraZeneca Postdoc Programme","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00204-021-03062-8","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T12:03:39Z","timestamp":1620389019000},"page":"2123-2136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Nephrotoxic antisense oligonucleotide SPC5001 induces kidney injury biomarkers in a proximal tubule-on-a-chip"],"prefix":"10.1007","volume":"95","author":[{"given":"Tom T. G.","family":"Nieskens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Magnusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"S\u00f6derberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5967-3440","authenticated-orcid":false,"given":"Anna-Karin","family":"Sj\u00f6gren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"issue":"4","key":"3062_CR1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1681\/asn.2015010060","volume":"27","author":"M Adler","year":"2016","unstructured":"Adler M, Ramm S, Hafner M et al (2016) A quantitative approach to screen for nephrotoxic compounds in vitro. J Am Soc Nephrol 27(4):1015\u20131028. https:\/\/doi.org\/10.1681\/asn.2015010060","journal-title":"J Am Soc Nephrol"},{"key":"3062_CR2","doi-asserted-by":"publisher","unstructured":"Babic JT, Manchandani P, Ledesma KR, Tam VH (2017) Evaluation of Urinary KIM-1 for Prediction of Polymyxin B-Induced Nephrotoxicity. Antimicrob Agents Chemother 61(11). https:\/\/doi.org\/10.1128\/aac.01735-17","DOI":"10.1128\/aac.01735-17"},{"issue":"42","key":"3062_CR3","doi-asserted-by":"publisher","first-page":"39739","DOI":"10.1074\/jbc.M200562200","volume":"277","author":"V Bailly","year":"2002","unstructured":"Bailly V, Zhang Z, Meier W, Cate R, Sanicola M, Bonventre JV (2002) Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem 277(42):39739\u201339748. https:\/\/doi.org\/10.1074\/jbc.M200562200","journal-title":"J Biol Chem"},{"issue":"10","key":"3062_CR4","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1038\/bjc.2013.619","volume":"109","author":"D Bianchini","year":"2013","unstructured":"Bianchini D, Omlin A, Pezaro C et al (2013) First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer 109(10):2579\u20132586. https:\/\/doi.org\/10.1038\/bjc.2013.619","journal-title":"Br J Cancer"},{"issue":"8","key":"3062_CR5","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1093\/nar\/gku142","volume":"42","author":"AD Burdick","year":"2014","unstructured":"Burdick AD, Sciabola S, Mantena SR et al (2014) Sequence motifs associated with hepatotoxicity of locked nucleic acid\u2013modified antisense oligonucleotides. Nucleic Acids Res 42(8):4882\u20134891. https:\/\/doi.org\/10.1093\/nar\/gku142","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"3062_CR6","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/nar\/gkv1210","volume":"44","author":"SA Burel","year":"2016","unstructured":"Burel SA, Hart CE, Cauntay P et al (2016) Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res 44(5):2093\u20132109. https:\/\/doi.org\/10.1093\/nar\/gkv1210","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"3062_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3109\/01480545.2013.834360","volume":"37","author":"D Burt","year":"2014","unstructured":"Burt D, Crowell SJ, Ackley DC, Magee TV, Aubrecht J (2014) Application of emerging biomarkers of acute kidney injury in development of kidney-sparing polypeptide-based antibiotics. Drug Chem Toxicol 37(2):204\u2013212. https:\/\/doi.org\/10.3109\/01480545.2013.834360","journal-title":"Drug Chem Toxicol"},{"issue":"6","key":"3062_CR8","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1021\/acs.molpharmaceut.7b00308","volume":"14","author":"P Caetano-Pinto","year":"2017","unstructured":"Caetano-Pinto P, Jamalpoor A, Ham J et al (2017) Cetuximab prevents methotrexate-induced cytotoxicity in vitro through epidermal growth factor dependent regulation of renal drug transporters. Mol Pharm 14(6):2147\u20132157. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00308","journal-title":"Mol Pharm"},{"issue":"6","key":"3062_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrd4309","volume":"13","author":"D Cook","year":"2014","unstructured":"Cook D, Brown D, Alexander R et al (2014) Lessons learned from the fate of AstraZeneca\u2019s drug pipeline: a five-dimensional framework. Nat Rev Drug Discovery 13(6):419\u2013431. https:\/\/doi.org\/10.1038\/nrd4309","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"3062_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/nat.2017.0693","volume":"28","author":"ST Crooke","year":"2018","unstructured":"Crooke ST, Baker BF, Pham NC et al (2018) The effects of 2\u2019-O-methoxyethyl oligonucleotides on renal function in humans. Nucleic Acid Ther 28(1):10\u201322. https:\/\/doi.org\/10.1089\/nat.2017.0693","journal-title":"Nucleic Acid Ther"},{"key":"3062_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.omtn.2017.11.004","volume":"10","author":"A Dieckmann","year":"2018","unstructured":"Dieckmann A, Hagedorn PH, Burki Y et al (2018) A sensitive in vitro approach to assess the hybridization-dependent toxic potential of high affinity gapmer oligonucleotides. Mol Therapy Nucl Acids 10:45\u201354. https:\/\/doi.org\/10.1016\/j.omtn.2017.11.004","journal-title":"Mol Therapy Nucl Acids"},{"issue":"1","key":"3062_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0192623314551840","volume":"43","author":"KS Frazier","year":"2015","unstructured":"Frazier KS (2015) Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective. Toxicol Pathol 43(1):78\u201389. https:\/\/doi.org\/10.1177\/0192623314551840","journal-title":"Toxicol Pathol"},{"issue":"4","key":"3062_CR13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1208\/s12248-011-9301-x","volume":"13","author":"TC Fuchs","year":"2011","unstructured":"Fuchs TC, Hewitt P (2011) Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology. AAPS J 13(4):615\u2013631. https:\/\/doi.org\/10.1208\/s12248-011-9301-x","journal-title":"AAPS J"},{"key":"3062_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.01.008","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"3062_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/ftd.0000000000000589","volume":"41","author":"BR Griffin","year":"2019","unstructured":"Griffin BR, Faubel S, Edelstein CL (2019) Biomarkers of drug-induced kidney toxicity. Ther Drug Monit 41(2):213\u2013226. https:\/\/doi.org\/10.1097\/ftd.0000000000000589","journal-title":"Ther Drug Monit"},{"issue":"5","key":"3062_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1089\/nat.2013.0436","volume":"23","author":"PH Hagedorn","year":"2013","unstructured":"Hagedorn PH, Yakimov V, Ottosen S et al (2013) Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucl Acid Ther 23(5):302\u2013310. https:\/\/doi.org\/10.1089\/nat.2013.0436","journal-title":"Nucl Acid Ther"},{"issue":"12","key":"3062_CR17","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/s1567-5769(02)00142-x","volume":"2","author":"SP Henry","year":"2002","unstructured":"Henry SP, Beattie G, Yeh G et al (2002) Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol 2(12):1657\u20131666. https:\/\/doi.org\/10.1016\/s1567-5769(02)00142-x","journal-title":"Int Immunopharmacol"},{"issue":"1\u20133","key":"3062_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.tox.2012.06.005","volume":"301","author":"SP Henry","year":"2012","unstructured":"Henry SP, Johnson M, Zanardi TA et al (2012) Renal uptake and tolerability of a 2\u2019-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey. Toxicology 301(1\u20133):13\u201320. https:\/\/doi.org\/10.1016\/j.tox.2012.06.005","journal-title":"Toxicology"},{"issue":"1\u20133","key":"3062_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.tox.2010.08.013","volume":"277","author":"D Hoffmann","year":"2010","unstructured":"Hoffmann D, Fuchs TC, Henzler T et al (2010) Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology 277(1\u20133):49\u201358. https:\/\/doi.org\/10.1016\/j.tox.2010.08.013","journal-title":"Toxicology"},{"issue":"9","key":"3062_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1039\/c3ib40049b","volume":"5","author":"KJ Jang","year":"2013","unstructured":"Jang KJ, Mehr AP, Hamilton GA et al (2013) Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integrative Biol 5(9):1119\u20131129. https:\/\/doi.org\/10.1039\/c3ib40049b","journal-title":"Integrative Biol"},{"key":"3062_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.omtn.2019.08.025","volume":"18","author":"MJ Janssen","year":"2019","unstructured":"Janssen MJ, Nieskens TTG, Steevels TAM et al (2019) Therapy with 2\u2019-O-Me phosphorothioate antisense oligonucleotides causes reversible proteinuria by inhibiting renal protein reabsorption. Mol Therapy Nucl Acids 18:298\u2013307. https:\/\/doi.org\/10.1016\/j.omtn.2019.08.025","journal-title":"Mol Therapy Nucl Acids"},{"issue":"1","key":"3062_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/toxsci\/kft278","volume":"138","author":"S Kakiuchi-Kiyota","year":"2014","unstructured":"Kakiuchi-Kiyota S, Koza-Taylor PH, Mantena SR et al (2014) Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice. Toxicol Sci 138(1):234\u2013248. https:\/\/doi.org\/10.1093\/toxsci\/kft278","journal-title":"Toxicol Sci"},{"issue":"1","key":"3062_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jinf.2012.01.015","volume":"65","author":"CJ Kubin","year":"2012","unstructured":"Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT (2012) Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 65(1):80\u201387. https:\/\/doi.org\/10.1016\/j.jinf.2012.01.015","journal-title":"J Infect"},{"issue":"2","key":"3062_CR24","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/mt.2011.260","volume":"20","author":"MW Lindholm","year":"2012","unstructured":"Lindholm MW, Elm\u00e9n J, Fisker N et al (2012) PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Therapy 20(2):376\u2013381. https:\/\/doi.org\/10.1038\/mt.2011.260","journal-title":"Mol Therapy"},{"key":"3062_CR25","doi-asserted-by":"publisher","unstructured":"Liu J, Pais GM, Avedissian SN et al (2020) Evaluation of Dose-Fractionated Polymyxin B on Acute Kidney Injury Using a Translational In Vivo Rat Model. Antimicrob Agents Chemother 64(5). https:\/\/doi.org\/10.1128\/aac.02300-19","DOI":"10.1128\/aac.02300-19"},{"issue":"6","key":"3062_CR26","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/atvbaha.112.248922","volume":"32","author":"AN Lyle","year":"2012","unstructured":"Lyle AN, Joseph G, Fan AE, Weiss D, Land\u00e1zuri N, Taylor WR (2012) Reactive oxygen species regulate osteopontin expression in a murine model of postischemic neovascularization. Arterioscler Thromb Vasc Biol 32(6):1383\u20131391. https:\/\/doi.org\/10.1161\/atvbaha.112.248922","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"3062_CR27","first-page":"258","volume":"2","author":"JK Marquis","year":"2000","unstructured":"Marquis JK, Grindel JM (2000) Toxicological evaluation of oligonucleotide therapeutics. Curr Opin Mol Ther 2(3):258\u2013263","journal-title":"Curr Opin Mol Ther"},{"key":"3062_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.omtn.2016.11.006","volume":"6","author":"A Moisan","year":"2017","unstructured":"Moisan A, Gubler M, Zhang JD et al (2017) Inhibition of EGF uptake by nephrotoxic antisense drugs in vitro and implications for preclinical safety profiling. Mol Therapy Nucl Acids 6:89\u2013105. https:\/\/doi.org\/10.1016\/j.omtn.2016.11.006","journal-title":"Mol Therapy Nucl Acids"},{"issue":"3","key":"3062_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd.2017.244","volume":"17","author":"P Morgan","year":"2018","unstructured":"Morgan P, Brown DG, Lennard S et al (2018) Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discovery 17(3):167\u2013181. https:\/\/doi.org\/10.1038\/nrd.2017.244","journal-title":"Nat Rev Drug Discovery"},{"issue":"12","key":"3062_CR30","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1124\/dmd.120.000098","volume":"48","author":"TTG Nieskens","year":"2020","unstructured":"Nieskens TTG, Persson M, Kelly EJ, Sj\u00f6gren AK (2020) A multicompartment human kidney proximal tubule-on-a-chip replicates cell polarization-dependent cisplatin toxicity. Drug Metab Disposition 48(12):1303\u20131311. https:\/\/doi.org\/10.1124\/dmd.120.000098","journal-title":"Drug Metab Disposition"},{"issue":"1","key":"3062_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/toxsci\/kfz021","volume":"169","author":"S Ramm","year":"2019","unstructured":"Ramm S, Todorov P, Chandrasekaran V et al (2019) A systems toxicology approach for the prediction of kidney toxicity and its mechanisms in vitro. Toxicols Sci 169(1):54\u201369. https:\/\/doi.org\/10.1093\/toxsci\/kfz021","journal-title":"Toxicols Sci"},{"key":"3062_CR32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.omtn.2017.06.013","volume":"8","author":"K Relizani","year":"2017","unstructured":"Relizani K, Griffith G, Echevarr\u00eda L et al (2017) Efficacy and safety profile of tricyclo-DNA antisense oligonucleotides in duchenne muscular dystrophy mouse model. Mol Therapy Nucl Acids 8:144\u2013157. https:\/\/doi.org\/10.1016\/j.omtn.2017.06.013","journal-title":"Mol Therapy Nucl Acids"},{"issue":"2","key":"3062_CR33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/toxsci\/kfs210","volume":"129","author":"J Saikumar","year":"2012","unstructured":"Saikumar J, Hoffmann D, Kim TM et al (2012) Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci 129(2):256\u2013267. https:\/\/doi.org\/10.1093\/toxsci\/kfs210","journal-title":"Toxicol Sci"},{"issue":"1","key":"3062_CR34","doi-asserted-by":"publisher","first-page":"14882","DOI":"10.1038\/s41598-018-33099-2","volume":"8","author":"C Sakolish","year":"2018","unstructured":"Sakolish C, Weber EJ, Kelly EJ et al (2018) Technology transfer of the microphysiological systems: a case study of the human proximal tubule tissue chip. Sci Rep 8(1):14882. https:\/\/doi.org\/10.1038\/s41598-018-33099-2","journal-title":"Sci Rep"},{"issue":"8","key":"3062_CR35","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1177\/0192623320964391","volume":"48","author":"\u00c5 Sandelius","year":"2020","unstructured":"Sandelius \u00c5, Basak J, H\u00f6ltt\u00e4 M et al (2020) Urinary kidney biomarker panel detects preclinical antisense oligonucleotide-induced tubular toxicity. Toxicol Pathol 48(8):981\u2013993. https:\/\/doi.org\/10.1177\/0192623320964391","journal-title":"Toxicol Pathol"},{"issue":"7","key":"3062_CR36","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3109\/1354750x.2011.613123","volume":"16","author":"D Sasaki","year":"2011","unstructured":"Sasaki D, Yamada A, Umeno H et al (2011) Comparison of the course of biomarker changes and kidney injury in a rat model of drug-induced acute kidney injury. Biomarkers 16(7):553\u2013566. https:\/\/doi.org\/10.3109\/1354750x.2011.613123","journal-title":"Biomarkers"},{"issue":"2","key":"3062_CR37","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1212\/nxg.0000000000000323","volume":"5","author":"DR Scoles","year":"2019","unstructured":"Scoles DR, Minikel EV, Pulst SM (2019) Antisense oligonucleotides: a primer. Neurology. Genetics 5(2):e323. https:\/\/doi.org\/10.1212\/nxg.0000000000000323","journal-title":"Genetics"},{"key":"3062_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.omtn.2018.11.005","volume":"14","author":"S Sewing","year":"2019","unstructured":"Sewing S, Gubler M, G\u00e9rard R et al (2019) GalNAc conjugation attenuates the cytotoxicity of antisense oligonucleotide drugs in renal tubular cells. Mol Therapy Nucl Acids 14:67\u201379. https:\/\/doi.org\/10.1016\/j.omtn.2018.11.005","journal-title":"Mol Therapy Nucl Acids"},{"issue":"4","key":"3062_CR39","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","volume":"46","author":"X Shen","year":"2018","unstructured":"Shen X, Corey DR (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucl Acids Res 46(4):1584\u20131600. https:\/\/doi.org\/10.1093\/nar\/gkx1239","journal-title":"Nucl Acids Res"},{"issue":"6","key":"3062_CR40","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","volume":"37","author":"W Shen","year":"2019","unstructured":"Shen W, De Hoyos CL, Migawa MT et al (2019) Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol 37(6):640\u2013650. https:\/\/doi.org\/10.1038\/s41587-019-0106-2","journal-title":"Nat Biotechnol"},{"issue":"10","key":"3062_CR41","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1007\/s00204-018-2284-y","volume":"92","author":"AK Sj\u00f6gren","year":"2018","unstructured":"Sj\u00f6gren AK, Breitholtz K, Ahlberg E et al (2018) A novel multi-parametric high content screening assay in ciPTEC-OAT1 to predict drug-induced nephrotoxicity during drug discovery. Arch Toxicol 92(10):3175\u20133190. https:\/\/doi.org\/10.1007\/s00204-018-2284-y","journal-title":"Arch Toxicol"},{"issue":"5","key":"3062_CR42","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1089\/nat.2012.0366","volume":"22","author":"R Stanton","year":"2012","unstructured":"Stanton R, Sciabola S, Salatto C et al (2012) Chemical modification study of antisense gapmers. Nucleic Acid Ther 22(5):344\u2013359. https:\/\/doi.org\/10.1089\/nat.2012.0366","journal-title":"Nucleic Acid Ther"},{"issue":"16","key":"3062_CR43","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1186\/1471-2105-15-s16-s16","volume":"15","author":"R Su","year":"2014","unstructured":"Su R, Li Y, Zink D, Loo LH (2014) Supervised prediction of drug-induced nephrotoxicity based on interleukin-6 and -8 expression levels. BMC Bioinformatics 15(16):S16. https:\/\/doi.org\/10.1186\/1471-2105-15-s16-s16","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"3062_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1208\/s12248-018-0245-2","volume":"20","author":"L Suter-Dick","year":"2018","unstructured":"Suter-Dick L, Mauch L, Ramp D et al (2018) Combining extracellular miRNA determination with microfluidic 3D cell cultures for the assessment of nephrotoxicity: a proof of concept study. AAPS J 20(5):86. https:\/\/doi.org\/10.1208\/s12248-018-0245-2","journal-title":"AAPS J"},{"issue":"2","key":"3062_CR45","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/nar\/gkl1071","volume":"35","author":"EE Swayze","year":"2007","unstructured":"Swayze EE, Siwkowski AM, Wancewicz EV et al (2007) Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 35(2):687\u2013700. https:\/\/doi.org\/10.1093\/nar\/gkl1071","journal-title":"Nucleic Acids Res"},{"key":"3062_CR46","unstructured":"USFDA (2018) Food and Drug Administration. Qualification of biomarker: clusterin (CLU), cystatin-C (CysC), kidney injury molecule-1 (KIM-1), N-acetylbeta-d-glucosaminidase (NAG), neutrophil gelatinase-associated lipocalin (NGAL), and osteopontin (OPN). http:\/\/www.fda.gov\/drugs\/cder-biomarker-qualification-program\/reviews-qualification-biomarker-clusterin-clucystatin-c-cysc-kidney-injury-molecule-1-kim-1-n. Accessed 26 Jan 2021"},{"issue":"2","key":"3062_CR47","doi-asserted-by":"publisher","first-page":"F517","DOI":"10.1152\/ajprenal.00291.2005","volume":"290","author":"VS Vaidya","year":"2006","unstructured":"Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV (2006) Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 290(2):F517\u2013F529. https:\/\/doi.org\/10.1152\/ajprenal.00291.2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"3062_CR48","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1146\/annurev.pharmtox.48.113006.094615","volume":"48","author":"VS Vaidya","year":"2008","unstructured":"Vaidya VS, Ferguson MA, Bonventre JV (2008a) Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 48:463\u2013493. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094615","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"3062_CR49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1752-8062.2008.00053.x","volume":"1","author":"VS Vaidya","year":"2008","unstructured":"Vaidya VS, Waikar SS, Ferguson MA et al (2008b) Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 1(3):200\u2013208. https:\/\/doi.org\/10.1111\/j.1752-8062.2008.00053.x","journal-title":"Clin Transl Sci"},{"issue":"5","key":"3062_CR50","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nbt.1623","volume":"28","author":"VS Vaidya","year":"2010","unstructured":"Vaidya VS, Ozer JS, Dieterle F et al (2010) Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 28(5):478\u2013485. https:\/\/doi.org\/10.1038\/nbt.1623","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3062_CR51","doi-asserted-by":"publisher","first-page":"e00292","DOI":"10.1002\/prp2.292","volume":"5","author":"L van Meer","year":"2017","unstructured":"van Meer L, van Dongen M, Moerland M, de Kam M, Cohen A, Burggraaf J (2017) Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects. Pharmacol Res Perspect 5(1):e00292. https:\/\/doi.org\/10.1002\/prp2.292","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"3062_CR52","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2013.02.359","volume":"62","author":"EP van Poelgeest","year":"2013","unstructured":"van Poelgeest EP, Swart RM, Betjes MG et al (2013) Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis 62(4):796\u2013800. https:\/\/doi.org\/10.1053\/j.ajkd.2013.02.359","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"3062_CR53","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/bcp.12738","volume":"80","author":"EP van Poelgeest","year":"2015","unstructured":"van Poelgeest EP, Hodges MR, Moerland M et al (2015) Antisense-mediated reduction of proprotein convertase subtilisin\/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial. Br J Clin Pharmacol 80(6):1350\u20131361. https:\/\/doi.org\/10.1111\/bcp.12738","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"3062_CR54","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1208\/s12248-018-0248-z","volume":"20","author":"MK Vormann","year":"2018","unstructured":"Vormann MK, Gijzen L, Hutter S et al (2018) Nephrotoxicity and kidney transport assessment on 3D perfused proximal tubules. AAPS J 20(5):90. https:\/\/doi.org\/10.1208\/s12248-018-0248-z","journal-title":"AAPS J"},{"key":"3062_CR55","doi-asserted-by":"publisher","unstructured":"Weber EJ, Lidberg KA, Wang L et al (2018) Human kidney on a chip assessment of polymyxin antibiotic nephrotoxicity. JCI Insight 3(24). https:\/\/doi.org\/10.1172\/jci.insight.123673","DOI":"10.1172\/jci.insight.123673"},{"issue":"5","key":"3062_CR56","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1046\/j.1523-1755.2001.00032.x","volume":"60","author":"Y Xie","year":"2001","unstructured":"Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F (2001) Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 60(5):1645\u20131657. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.00032.x","journal-title":"Kidney Int"},{"issue":"2","key":"3062_CR57","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1124\/jpet.112.197426","volume":"343","author":"TA Zanardi","year":"2012","unstructured":"Zanardi TA, Han SC, Jeong EJ et al (2012) Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2. J Pharmacol Exp Ther 343(2):489\u2013496. https:\/\/doi.org\/10.1124\/jpet.112.197426","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"3062_CR58","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1086\/507488","volume":"79","author":"Z Zhao","year":"2006","unstructured":"Zhao Z, Tuakli-Wosornu Y, Lagace TA et al (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 79(3):514\u2013523. https:\/\/doi.org\/10.1086\/507488","journal-title":"Am J Hum Genet"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-021-03062-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-021-03062-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-021-03062-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:49:58Z","timestamp":1622508598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-021-03062-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["3062"],"URL":"https:\/\/doi.org\/10.1007\/s00204-021-03062-8","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"assertion":[{"value":"12 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tom Nieskens, Otto Magnusson, Magnus S\u00f6derberg, Patrik Andersson, Mikael Persson and Anna-Karin Sj\u00f6gren are employees of AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Human-derived renal proximal tubule epithelial cells (HRPTEC) used in this study were commercially obtained from Biopredic as \u2018cryopreserved human renal proximal tubular cells\u2019, reference code \u2018RPT101\u2019, batch \u2018RPT101030\u2019.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Additional declarations"}},{"value":"The data produced in this study utilized human-derived cells that were procured from Biopredic, which provides de-identified samples, and stored in the AstraZeneca BioBank Gothenburg.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}